Executive Overview: The High-Acuity Spectrum of ANCA Glomerulonephritis

ANCA-associated vasculitis (AAV) encompasses a group of systemic necrotizing small-vessel vasculitides predominantly mediated by antineutrophil cytoplasmic antibodies. The clinical continuum includes Granulomatosis with Polyangiitis (GPA, formerly Wegener’s granulomatosis), Microscopic Polyangiitis (MPA), and, less frequently, Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Renal involvement presents clinically as a rapidly progressive glomerulonephritis (RPGN), which is pathologically characterized on renal biopsy as a pauci-immune necrotizing and crescentic glomerulonephritis. The hallmark features include segmental fibrinoid necrosis of the glomerular capillary tuft and crescent formation with minimal to absent immunoglobulin or complement deposition on direct immunofluorescence.

Untreated, ANCA-associated glomerulonephritis carries a one-year mortality rate approaching eighty to ninety percent, primarily driven by uremia, systemic vasculitic failure, or acute alveolar hemorrhage.

Modern immunosuppressive therapy has converted this fatal condition into a chronic, relapsing disorder with five-year survival rates exceeding eighty percent.

However, treatment toxicity—principally opportunistic infections, secondary malignancies, leukopenia, and cardiovascular events—now rivals active vasculitis as the primary cause of early patient mortality.

The therapeutic framework divides into two sequential, distinct phases:

• Induction of Remission: Aggressive, rapid suppression of systemic inflammation and immune-mediated glomerular necrosis to halt active crescent formation, prevent end-stage renal disease (ESRD), and preserve functioning nephrons.
• Maintenance of Remission: Sustained, lower-intensity targeted immunosuppression designed to prevent disease relapse while minimizing drug-induced end-organ toxicity.

1. Pre-Therapeutic Risk Stratification and Serological Profiling

Optimal therapeutic regimen selection depends on distinguishing between organ-threatening and non-organ-threatening presentations, as well as mapping the serological profile.

PR3-ANCA vs. MPO-ANCA Phenotypes

While clinical trial stratification historically separated patients by GPA versus MPA classification, genetic and longitudinal cohort data confirm that the serological ANCA subtype (anti-proteinase 3 [PR3] versus anti-myeloperoxidase [MPO]) is a superior predictor of relapse propensity, histological chronicity, and therapeutic response:

• PR3-ANCA (Cytoplasmic / c-ANCA): Classically associated with GPA. Characterized by prominent granulomatous upper and lower respiratory tract lesions, high inflammatory turnover, acute cellular crescents on biopsy, and an inherently high risk of clinical relapse (up to 50% within five years).
• MPO-ANCA (Perinuclear / p-ANCA): Classically associated with MPA. Typically exhibits isolated renal-limited vasculitis or fibrosing interstitial pulmonary disease, presents with higher baseline chronic interstitial fibrosis and glomerulosclerosis on biopsy, and carries a substantially lower relapse rate (approximately 15% to 20% at five years).

Disease Acuity Tiers

Under European Alliance of Associations for Rheumatology (EULAR) and Kidney Disease: Improving Global Outcomes (KDIGO) definitions, renal involvement automatically categorizes a patient as having Organ- or Life-Threatening AAV:

• Characterized by a rising serum creatinine, an active urinary sediment (dysmorphic hematuria and red blood cell casts), and proteinuria.
• Concomitant diffuse alveolar hemorrhage (DAH), acute mesenteric ischemia, or central nervous system vasculitis elevates acuity, requiring immediate hospitalization and continuous hemodynamic and pulmonary surveillance.

2. Remission Induction Regimens: Aggressive Immunosuppression

Induction therapy must be deployed immediately upon clinical suspicion and renal biopsy confirmation, combining high-dose corticosteroids with targeted B-cell depletion or alkylating chemotherapy.

Targeted B-Cell Depletion: Rituximab (The Preferred Standard)

Rituximab is a chimeric monoclonal antibody directed against the CD20 surface antigen on pre-B and mature B lymphocytes, initiating complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.

• Clinical Evidence: Landmark randomized controlled trials (RAVE and RITUXVAS) established that rituximab is non-inferior to cyclophosphamide for general renal induction and statistically superior for the induction of PR3-ANCA-positive and relapsing disease.
• Dosing Schedules:

• The standard lymphoma protocol: 375 mg/m² body surface area administered as four consecutive weekly intravenous infusions.
• The rheumatology/vasculitis protocol: Fixed dose of 1,000 mg intravenously administered on Day 0 and Day 14 (two doses total). Both protocols yield equivalent efficacy and B-cell depletion profiles.

• Advantages: Avoids alkylating gonadotoxicity, reduces bladder toxicity, and eliminates cumulative secondary malignancy risks associated with cyclophosphamide.

Alkylating Chemotherapy: Cyclophosphamide

Cyclophosphamide cross-links DNA strands, inhibiting DNA replication and suppressing rapidly dividing effector T and B lymphocytes.

• Primary Indications: Preferred in patients presenting with severe renal impairment (eGFR < 15\text{ mL/min/1.73 m²} or serum creatinine > 4.0\text{ mg/dL}) paired with active cellular crescents, concomitant diffuse alveolar hemorrhage requiring mechanical ventilation, or in resource-constrained environments where rituximab is unavailable.
• Intravenous Pulse vs. Daily Oral Protocols:

• Intravenous Pulse Protocol (CYCLOPS Regimen - Preferred): 15 mg/kg (maximum single dose 1,200 mg), adjusted downward for age > 60\text{ years} and renal clearance, administered every two to three weeks for three to six months (total 3 to 6 pulses).
• Advantage: Delivers approximately half the cumulative lifetime dose of daily oral regimens (1.5 to 2.0 mg/kg/day), matching efficacy while reducing leukopenia, severe infections, and bladder cancer risk.

• Toxicity Mitigations: Co-administration of Mesna (sodium 2-mercaptoethanesulfonate) to neutralize acrolein, preventing hemorrhagic cystitis, alongside forced hydration and strict weekly complete blood count monitoring (targeting absolute neutrophil counts > 1,500/\mu\text{L}).

Corticosteroid Modernization: The PEXIVAS Protocol

Historically, high-dose intravenous methylprednisolone pulses (500 to 1,000 mg daily for three days) were followed by aggressive, prolonged high-dose oral prednisone (1 mg/kg/day).

• The PEXIVAS Paradigm: The PEXIVAS trial demonstrated that a reduced-dose oral glucocorticoid regimen was non-inferior to a standard high-dose regimen regarding death or end-stage renal disease, while reducing serious infections by more than thirty percent within the first year.
• Tapering Dynamics: Following initial IV methylprednisolone, oral prednisone is initiated at approximately 1 mg/kg/day, but tapered rapidly downward to reach 10 mg/day by week twelve, and 5 mg/day by month six.

Targeted Complement C5a Inhibition: Avacopan

The alternative complement pathway drives small-vessel vasculitic necrosis: C5a binding to the C5a receptor-1 (C5aR1 / CD88) on neutrophils triggers priming, migration, and degranulation.

• Mechanism and Trial Data: Avacopan is an orally bioavailable, selective small-molecule C5aR1 antagonist. The Phase III ADVOCATE trial established that avacopan (30 mg twice daily with food for 52 weeks) paired with rituximab or cyclophosphamide was non-inferior to standard glucocorticoid tapers at week 26 and superior in sustaining remission at week 52, while demonstrating greater recovery of glomerular filtration rate (eGFR).
• Steroid-Sparing Impact: Avacopan enables the substantial reduction or near-elimination of maintenance oral corticosteroids, lowering glucocorticoid-induced comorbidities (diabetes, osteoporosis, avascular necrosis, psychiatric disturbance).

The Evolving Role of Plasma Exchange (PLEX)

• The PEXIVAS Findings: Routine therapeutic plasma exchange was previously standard for severe renal vasculitis (serum creatinine > 5.7\text{ mg/dL}) or pulmonary hemorrhage. The PEXIVAS trial definitively proved that adding plasma exchange to standard immunosuppression did not reduce the incidence of death or end-stage renal disease across the general population.
• Restricted Current Indications: Therapeutic plasma exchange is reserved for explicit refractory settings: concurrent anti-glomerular basement membrane (anti-GBM) antibody disease (double-positive vasculitis), severe life-threatening diffuse alveolar hemorrhage with refractory hypoxemia, or rapidly advancing RPGN that fails to respond to induction therapy.

3. Maintenance of Remission Regimens: Sustained Relapse Prevention

Induction therapy transitions into the maintenance phase upon achieving clinical remission—defined as the complete absence of active clinical vasculitic features and normalization of inflammatory markers (typically between month three and month six).

B-Cell Suppression: Maintenance Rituximab (The MAINRITSAN Standard)

• Clinical Superiority: The prospective randomized MAINRITSAN trials demonstrated that fixed-schedule, low-dose rituximab is statistically superior to azathioprine for preventing major vasculitic relapses.
• Dosing Protocols:

• Fixed-Schedule Protocol: 500 mg intravenously administered at months 6, 12, 18, 24, and 30 following induction.
• Serology- and B-Cell-Guided Protocol: Dosing triggered by the reconstitution of CD19+ B-cells or a rising/reappearing ANCA titer. However, fixed dosing remains the standard due to lower breakthrough rates.

• Safety Auditing: Prolonged maintenance rituximab requires serial tracking of serum quantitative immunoglobulins (IgG) prior to every infusion, as severe secondary hypogammaglobulinemia (< 300\text{–}400\text{ mg/dL}) carries severe respiratory tract infection risks, requiring intravenous immunoglobulin (IVIG) replacement.

Oral Maintenance Alternatives

• Azathioprine:

• Mechanism and Dosing: A purine synthesis antagonist dosed at 1.5 to 2.0 mg/kg/day, combined with low-dose oral glucocorticoids.
• Mandatory Pre-Screening: Prior to initiating azathioprine, the patient must undergo testing for Thiopurine S-Methyltransferase (TPMT) or NUDT15 enzymatic activity/genotype. Patients with homozygous or intermediate deficiency cannot clear toxic thiopurine metabolites, precipitating fatal, unmitigated bone marrow aplasia.

• Mycophenolate Mofetil (MMF):

• Mechanism and Dosing: Selective inosine monophosphate dehydrogenase (IMPDH) inhibitor dosed at 1,000 mg twice daily (2 g/day).
• Clinical Standing: The IMPROVE trial demonstrated that MMF is inferior to azathioprine in preventing relapses in general AAV. It is reserved for patients who cannot tolerate azathioprine and carry contraindications to rituximab.

• Methotrexate:

• Standing: Contraindicated in patients with moderate-to-severe renal impairment (\text{eGFR} < 45\text{–}60\text{ mL/min/1.73 m²}) due to impaired renal tubular drug clearance and life-threatening myelosuppressive toxicity.

Maintenance Duration and Discontinuation Protocols

• Minimum Horizon: Maintenance immunosuppression must continue for a minimum of 24 to 36 months following induction of remission.
• Extended Duration: In patients with PR3-ANCA positivity, high historical relapse burden, persistently elevated ANCA titers, or ongoing organ risk, maintenance therapy is extended to 48 to 60 months or maintained indefinitely.

4. Structural Comparison: Clinical Profiles of Primary Immunosuppressive Modalities

Evaluating the pharmacological mechanisms, therapeutic niches, and clinical toxicity profiles illustrates how modern agents balance immunosuppressive potency against host safety:

Rituximab (Anti-CD20 Monoclonal Antibody)

• Therapeutic Phase: Primary first-line induction; gold-standard maintenance agent.
• Clinical Target: Membrane-bound CD20 antigen across circulating and tissue-resident pre-B and mature B lymphocytes.
• Optimal Clinical Profile: PR3-ANCA-positive disease, relapsing vasculitis, childbearing-potential individuals requiring fertility preservation, and secondary maintenance.
• Dose-Limiting Toxicities: Infusion-related reactions, severe progressive secondary hypogammaglobulinemia, late-onset neutropenia, and high susceptibility to encapsulated bacterial and viral infections.

Cyclophosphamide (Alkylating Nitrogen Mustard)

• Therapeutic Phase: Emergency first-line induction; strictly contraindicated for maintenance therapy.
• Clinical Target: DNA intra-strand and inter-strand cross-linking across actively proliferating lymphocytes.
• Optimal Clinical Profile: Severe crescentic glomerulonephritis with \text{eGFR} < 15\text{ mL/min/1.73 m²}, concurrent life-threatening diffuse alveolar hemorrhage, or rituximab intolerance.
• Dose-Limiting Toxicities: Dose-dependent bone marrow aplasia, urothelial toxicity (acrolein-induced hemorrhagic cystitis and bladder carcinoma), irreversible ovarian failure/premature menopause, and late myelodysplastic syndromes.

Avacopan (Selective C5aR1 Antagonist)

• Therapeutic Phase: Modern adjunctive induction; chronic steroid-sparing maintenance agent.
• Clinical Target: G-protein-coupled C5a receptor-1 (CD88) on polymorphonuclear neutrophils.
• Optimal Clinical Profile: Patients with high vulnerability to glucocorticoid toxicity: severe pre-existing diabetes, advanced osteoporosis, active psychiatric disorders, or elderly cohorts.
• Dose-Limiting Toxicities: Asymptomatic elevations in hepatic transaminases (ALT/AST requiring routine liver panel monitoring), headaches, and upper respiratory tract infections.

Azathioprine (Purine Synthesis Antagonist)

• Therapeutic Phase: Second-line oral maintenance; never utilized for induction of remission.
• Clinical Target: Intracellular conversion to 6-thioguanine nucleotides (6-TGN), blocking purine nucleotide incorporation into DNA.
• Optimal Clinical Profile: Stable MPO-ANCA maintenance in patients who achieve complete remission and have normal TPMT/NUDT15 enzymatic function.
• Dose-Limiting Toxicities: Severe myelosuppression, hepatotoxicity, acute pancreatitis, cutaneous hypersensitivity, and secondary cutaneous non-melanoma skin malignancies.

5. Supportive Care, Infection Prophylaxis, and Monitoring Protocols

In modern clinical trials, early mortality in ANCA-associated vasculitis is driven by iatrogenic immunosuppressive toxicity and opportunistic infections rather than uncontrolled vascular inflammation. Supportive care regimens are mandatory components of the clinical protocol.

Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis

• The Mandate: Profound B-cell depletion from rituximab combined with glucocorticoids and cyclophosphamide severely compromises cell-mediated host defenses, making patients susceptible to fulminant Pneumocystis jirovecii pneumonia.
• First-Line Pharmacological Protocol: Trimethoprim-Sulfamethoxazole (TMP-SMX) administered at a dosage of one single-strength tablet (80/400 mg) daily or one double-strength tablet (160/800 mg) three times weekly.
• Duration: Maintained continuously throughout active induction therapy and for a minimum of six months post-rituximab infusion or until absolute CD4+ T-cell counts rebound above 200/\mu\text{L}.
• Second-Line Alternatives: In patients with documented sulfa allergy or severe glucose-6-phosphate dehydrogenase (G6PD) deficiency:

• Atovaquone oral suspension (1,500 mg daily with fatty meals).
• Inhaled monthly nebulized Pentamidine (300 mg).
• Oral Dapsone (100 mg daily, only after confirming normal G6PD levels).

Infectious and Bone Health Defense

• Screening for Latent Pathogens: Prior to initiating rituximab or cyclophosphamide, patients must undergo mandatory screening for Hepatitis B (HBsAg and Anti-HBc), Hepatitis C (Anti-HCV), and Latent Tuberculosis (IGRA / QuantiFERON).
• Occult Hepatitis B carriage warrants prophylactic entecavir coverage to prevent fulminant viral reactivation during B-cell depletion.
• Vaccination Calendars: Annual non-live influenza vaccination, modernized SARS-CoV-2 boosters, and sequential pneumococcal immunization (PCV15/20 followed by PPSV23) should ideally be completed at least two weeks before B-cell depletion, or administered during maintenance intervals when minor humoral responses can still occur.
• Bone Protection: All patients receiving systemic corticosteroids must receive daily calcium (1,000 to 1,200 mg) and Vitamin D (800 to 1,000 IU) supplementation, paired with baseline dual-energy X-ray absorptiometry (DEXA) scanning and early oral bisphosphonate therapy if osteoporosis or high fracture risk is documented.

Longitudinal Laboratory Surveillance Cadence

• Active Induction Phase: Complete blood counts, serum creatinine, eGFR, liver enzymes, and quantitative urine protein-to-creatinine ratio (UPCR) assessed every one to two weeks.
• Maintenance Phase: Biochemical and hematological surveillance executed every one to two months.
• ANCA Titer Interpretation: ANCA titers must be monitored regularly; however, clinical management should never treat an isolated serological rise without objective clinical, urinalytic, or histological signs of active vasculitis.

6. Phased Implementation Protocol: The Longitudinal Clinical Roadmap

Executing a synchronized, risk-mitigated care trajectory across the patient's disease continuum requires a phased operational protocol:

• Phase 1: Hyper-Acute Diagnostic Confirmation and Induction Initiation (Weeks 1 to 2):

• Confirm diagnosis via rapid indirect immunofluorescence and formal enzyme-linked immunosorbent assay (anti-PR3 and anti-MPO IgG).
• Perform emergency ultrasound-guided percutaneous renal biopsy to quantify the percentage of active cellular crescents versus chronic global glomerulosclerosis (Berden histopathological classification).
• Exclude active systemic infections and latent viral carriage (Hepatitis B, C, HIV, TB).
• Initiate IV pulse methylprednisolone (500 to 1,000 mg daily for three days).
• Administer initial Rituximab infusion (Day 0) or initial IV cyclophosphamide pulse; prescribe oral TMP-SMX for PJP prophylaxis.

• Phase 2: Consolidation and Glucocorticoid De-escalation (Weeks 3 to 12):

• Complete induction course (second Rituximab infusion at Day 14, or scheduled bi-weekly cyclophosphamide pulses).
• Execute rapid oral prednisone taper following the PEXIVAS reduced-dose schedule, targeting 10 to 15 mg daily by week twelve, or deploy adjunctive Avacopan to reduce steroid exposure.
• Monitor serial serum creatinine, active urine sediment clearing, and absolute neutrophil counts weekly.

• Phase 3: Remission Transition and Maintenance Deployment (Months 4 to 6):

• Formally evaluate remission status at month three to six using the Birmingham Vasculitis Activity Score (BVAS); confirm BVAS equals zero.
• Check quantitative serum immunoglobulins (IgG) and peripheral blood flow cytometry for complete CD19+ B-cell depletion.
• Initiate maintenance therapy at Month 6: administer first maintenance Rituximab infusion (500 mg IV), or verify normal TPMT status and begin oral Azathioprine (2 mg/kg/day).
• Taper oral prednisone completely off or maintain at a low physiological dose (\le 5\text{ mg daily}).

• Phase 4: Chronic Relapse Surveillance and Immunological Auditing (Months 7 to 36+):

• Administer scheduled maintenance Rituximab (500 mg IV every six months) through month thirty.
• Perform longitudinal surveillance every eight to twelve weeks: tracking blood pressure, urinalysis for microscopic hematuria, UPCR, eGFR, and quantitative ANCA titers.
• Audit for long-term complications: screen for non-melanoma skin cancers, assess cardiovascular risk parameters, and evaluate for late infectious hypogammaglobulinemia.

Strategic Summary: The Modern Nephrological Paradigm

The management of ANCA-associated glomerulonephritis has shifted from broad, non-specific cytotoxic chemotherapy toward targeted, mechanism-specific immunomodulation.

By prioritizing Rituximab over alkylating agents, implementing the PEXIVAS reduced-dose glucocorticoid taper, utilizing Avacopan to disrupt alternative complement signaling, and restricting plasma exchange to defined ultra-high-risk cohorts, clinicians can induce complete clinical remission while protecting patients from life-threatening immunosuppressive toxicity.

Transitioning patients onto structured, low-dose maintenance Rituximab for a minimum of two to three years consolidates renal recovery, reduces long-term relapse rates, and preserves vital renal architecture.

10 Frequently Asked Questions (FAQs)

Q1. What is the fundamental histological hallmark of ANCA glomerulonephritis on renal biopsy?

The hallmark histological lesion is a pauci-immune necrotizing and crescentic glomerulonephritis.

Light microscopy demonstrates segmental fibrinoid necrosis of the glomerular capillary tufts with cellular or fibrocellular crescent formation in Bowman's space, while direct immunofluorescence reveals an absence or trace presence ("pauci-immune") of immunoglobulin (IgG, IgA, IgM) and complement (C3, C1q) deposition, distinguishing it from immune-complex glomerulonephritis (such as lupus nephritis or IgA nephropathy) and anti-GBM disease.

Q2. Why is Rituximab preferred over Cyclophosphamide for induction in PR3-ANCA disease?

Prospective randomized trial data (specifically the RAVE trial) confirmed that rituximab is non-inferior to cyclophosphamide for general induction, but statistically superior in patients presenting with PR3-ANCA-positive vasculitis and those with disease relapses.

Furthermore, rituximab preserves gonadal function (avoiding premature ovarian failure and male azoospermia) and eliminates the cumulative lifetime risks of bladder cancer and secondary myelodysplasia associated with cyclophosphamide.

Q3. When is Cyclophosphamide still the preferred first-line induction agent?

Cyclophosphamide remains preferred in:

• Patients presenting with severe advanced renal failure (baseline serum creatinine > 4.0\text{ mg/dL} or \text{eGFR} < 15\text{ mL/min/1.73 m²}) paired with extensive active cellular crescents on biopsy.
• Patients presenting with concurrent severe diffuse alveolar hemorrhage causing respiratory failure.
• Resource-limited health systems where the high cost or logistical availability of monoclonal antibodies restricts access to rituximab.

Q4. What did the PEXIVAS clinical trial conclude regarding Plasma Exchange (PLEX)?

The landmark PEXIVAS trial evaluated 704 patients with severe ANCA-associated vasculitis and concluded that routine therapeutic plasma exchange did not reduce the long-term incidence of death or end-stage renal disease (ESRD) compared to standard care.

Consequently, international clinical guidelines no longer recommend routine plasma exchange for general severe AAV, restricting its deployment to dual anti-GBM/ANCA-positive disease, severe refractory pulmonary hemorrhage, or failing salvage scenarios.

Q5. How does Avacopan change the management of corticosteroid toxicities?

Avacopan selectively blocks the C5a receptor-1 (C5aR1 / CD88), which prevents the terminal priming and activation of neutrophils without suppressing upstream C3-mediated host defenses.

By replacing high-dose maintenance corticosteroids, avacopan significantly reduces glucocorticoid-related side effects (such as metabolic dysfunction, accelerated osteoporosis, cataracts, and systemic psychiatric disturbances) while achieving superior long-term eGFR recovery and higher sustained remission rates at one year.

Q6. Why is Trimethoprim-Sulfamethoxazole (TMP-SMX) mandatory during induction therapy?

Aggressive induction therapy combining high-dose corticosteroids with rituximab or cyclophosphamide induces marked B-cell depletion and cellular immune deficits, predisposing patients to life-threatening Pneumocystis jirovecii pneumonia (PJP).

Prophylactic low-dose TMP-SMX (single-strength daily or double-strength three times weekly) reduces the incidence of PJP by over ninety percent and must be maintained throughout active induction and until cellular immune markers normalize.

Q7. Why must Thiopurine Methyltransferase (TPMT) testing precede Azathioprine therapy?

Azathioprine is metabolized into active 6-thioguanine nucleotides, which are subsequently broken down and inactivated by the enzymes TPMT and NUDT15:

• If a patient carries homozygous or intermediate genetic mutations leading to enzymatic deficiency, toxic active metabolites accumulate rapidly.
• This precipitates catastrophic, life-threatening bone marrow aplasia and profound pancytopenia.

Testing ensures that patients with deficient enzymatic clearance are identified and excluded from azathioprine therapy.

Q8. What is the recommended duration of maintenance immunosuppression for ANCA vasculitis?

Current KDIGO and EULAR guidelines mandate a minimum maintenance duration of 24 to 36 months following successful induction of remission.

In patients with high-risk features—such as PR3-ANCA serology, a history of multiple clinical relapses, or persistently rising ANCA titers with persistent microscopic hematuria—maintenance therapy with low-dose rituximab is extended to 48 to 60 months, or maintained indefinitely.

Q9. Should an isolated increase in ANCA titer trigger immediate treatment escalation?

No. An isolated rise in ANCA titer alone is insufficient to warrant treatment escalation:

• A rising ANCA titer increases the statistical likelihood of an impending clinical relapse, but up to forty percent of patients with elevated titers remain in stable, long-term remission.
• Therapeutic escalation carries toxic risks and should only occur if the rising titer is accompanied by objective signs of active organ vasculitis: new or worsening dysmorphic hematuria, cellular red blood cell casts, rising serum creatinine, new pulmonary infiltrates, or systemic inflammatory symptoms.

Q10. What is secondary hypogammaglobulinemia, and how is it monitored during Rituximab maintenance?

Secondary hypogammaglobulinemia is a progressive decline in systemic serum immunoglobulin G (IgG) levels resulting from repeated, long-term B-cell depletion.

Serum quantitative IgG levels must be measured prior to every six-month maintenance infusion:

• If serum IgG drops below 300\text{ to }400\text{ mg/dL} and the patient experiences recurrent sinopulmonary bacterial infections, rituximab must be temporarily suspended.
• The patient should be evaluated for subcutaneous or intravenous immunoglobulin (IVIG) replacement therapy to restore functional humoral immunity.